Related Experiment Video

Updated: Jul 9, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

[Direct thrombin inhibition in interventional cardiology. The ACUITY trial]

H Heinze1, H Darius

  • 1Vivantes Klinikum Neukölln, Kardiologie und konservative Intensivmedizin, Rudower Strasse 48, 12351 Berlin.

Hamostaseologie
|December 7, 2007
PubMed

Insights

Bivalirudin alone, a direct thrombin inhibitor, proved comparable to heparin plus glycoprotein IIb/IIIa inhibitors for preventing ischaemic events in acute coronary syndrome patients. This regimen also significantly reduced bleeding complications.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Context:

  • Acute non-ST-segment elevation coronary syndrome (ACS) management.
  • Evaluation of early invasive treatment strategies.
  • Comparison of antithrombotic therapies.

Purpose:

  • To compare the efficacy and safety of three therapeutic regimens in patients with ACS undergoing an early invasive strategy.
  • To assess bivalirudin monotherapy against standard care (heparin plus glycoprotein IIb/IIIa inhibitor) and combination therapy (bivalirudin plus GPI).

Summary:

  • The ACUITY Trial randomized 13,819 ACS patients to heparin plus GPI, bivalirudin plus GPI, or bivalirudin alone.
  • Bivalirudin monotherapy demonstrated non-inferiority to heparin plus GPI regarding ischaemic event rates.
  • A significantly lower rate of bleeding complications was observed with bivalirudin alone compared to heparin plus GPI.

Impact:

  • Highlights bivalirudin's potential as a safer alternative in ACS treatment, particularly in reducing bleeding risks.
  • Provides evidence supporting the use of bivalirudin monotherapy within an early invasive strategy for ACS.
  • Informs clinical decision-making regarding antithrombotic selection for ACS patients.

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...